Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 12/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025668 | 0.84 | AKR1C3 (0.46) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025699 | 0.82 | MEN1 (0.47) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025654 | 0.79 | MEN1 (0.51) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025670 | 0.79 | AKR1C3 (0.40) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025669 | 0.78 | AKR1C3 (0.38) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025703 | 0.78 | NAMPT (0.56) | AKR1C3KMT2ANAMPTNPC1 | |
| SCHEMBL14025659 | 0.78 | MEN1 (0.64) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025660 | 0.78 | AKR1C3 (0.53) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025661 | 0.77 | AKR1C3 (0.62) | AKR1C3AKR1C1MEN1KMT2APOLB | |
| SCHEMBL14025656 | 0.76 | HDAC1 (0.48) | AKR1C3AKR1C1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | AKR1C3 518/4885AKR1C1 528/4885MEN1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.